AFT PHARMACEUTICALS LIMITED — Director's Dealing 2018

Aug 21, 2018

==> picture [110 x 26] intentionally omitted <==

Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

ToNZX Limited; and
Name of listed issuer:		AFT PharmaceuticalsLimited (AFT)
Date this disclosure made:		22-Aug-18
Date of last disclosure:		11-Jul-17
Director or senior manager giving disclosure
Full name(s):		JamesBurns
Name of listed issuer:		AFT PharmaceuticalsLimited (AFT)
Name of related body corporate (if applicable):		Not applicable
Position held in listed issuer:		Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:		Fully-Paid Ordinary Sharesin AFT
Nature of the affected relevant interest(s):		Registeredholderand beneficialownerofordinary shares
For that relevant interest-
Number held in class before acquisition or disposal:		100,417
Number held in class after acquisition or disposal:		125,417
Current registered holder(s):		Unknown
Registered holder(s) once transfers are registered:		James Stephen Burns
Details of transactions giving rise to acquisition or disposal
Total numberoftransactions towhich noticerelates:		1
Details of transactions requiring disclosure-
Date oftransaction:		21-Aug-18
Nature oftransaction:		On-market acquisitionofordinary shares
Name ofany otherparty orparties to the transaction(if known):		Unknown
The consideration, expressed in New Zealand dollars, paid or received for the acquisition ordisposal. If the consideration was not in cash and cannot be readily by converted into a cash value,describe the consideration:		NZ$2.255 pershare / $56,400.00
Numberof financialproducts towhichthe transaction related:		25,000
If the issuer has a financial products trading policy that prohibits directors or senior managers fromtrading during any period without written clearance (a closed period) include the following details—
Whether relevantinterestswere acquired ordisposed ofduring a closed period:		No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed duringthe closed period:		Not applicable
Date of the prior written clearance (if any):		Not applicable
Summary of other relevant interests after acquisition or disposal:
Class ofquotedfinancialproducts:		Not applicable
Nature of relevantinterest:		Not applicable
_For that relevant interest,- _
Number heldinclass:		Not applicable
Currentregisteredholder(s):		Not applicable
For a derivative relevant interest,-
Type ofderivative:		Not applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial products(if any):		Not applicable
A statement as to whether the derivative is cash settled or physically settled:		Not applicable
Maturity date of the derivative (if any):		Not applicable
Expiry date of the derivative (if any):		Not applicable
The price's specified terms (if any):		Not applicable
Any other details needed to understand how the amount of the consideration payable under thederivative or the value of the derivative is affected by the value of the underlying financial products:		Not applicable
For that derivative relevant interest,-
Parties to the derivative:		Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant interest inthe derivative:		Not applicable
Certification
I certify that, to the best of my knowledge and belief, the information contained in this disclosure iscorrect and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:		22-Aug-18

==> picture [505 x 34] intentionally omitted <==